• An Overview of Drug Discovery and Development
• 78 min
  1. Rules and filters and their impact on success in chemical biology and drug discovery

  • Dr. Christopher Lipinski
• 37 min
  2. Where did drugs come from?

  • Dr. David Swinney
• Target Selection in Early Stage Drug Discovery
• 42 min
  3. G-Protein coupled receptors in drug discovery

  • Dr. Mark Wigglesworth
• 42 min
  4. Enzymology in drug discovery 1

  • Prof. Robert Copeland
• 66 min
  5. Enzymology in drug discovery 2

  • Prof. Robert Copeland
• 41 min
  6. Inhibiting protein-protein interactions 1

  • Dr. Adrian Whitty
• 35 min
  7. Inhibiting protein-protein interactions 2

  • Dr. Adrian Whitty
• Key Drug Discovery Challenges in Major Therapeutic Areas
• 64 min
  8. Current trends in antiviral drug development

  • Prof. Dr. Erik De Clercq
• 27 min
  9. The challenge of developing drugs for neglected parasitic diseases

  • Prof. James Mckerrow
• 55 min
  10. Is there a role for academia in drug discovery

  • Dr. Adrian J. Ivinson
• 31 min
  11. Key drug discovery challenges in cardiovascular medicine

  • Dr. Dan Swerdlow
  • Dr. Michael V. Holmes
• Methods of Hit Identification
• 46 min
  12. Fragment-based lead discovery

  • Dr. Daniel A. Erlanson
• Medicinal Chemistry and SAR
• 53 min
  13. Hit to lead

  • Dr. Michael Rafferty
• 37 min
  14. Prodrug strategies to overcome problems in drug therapy

  • Prof. Jarkko Rautio
• 40 min
  15. Deep ocean microorganisms yield mechanistically-novel anticancer agents

  • Prof. William Fenical
• From Lead to Drug
• 25 min
  16. Biomarkers in drug development: potential use and challenges

  • Dr. Abdel-Bassett Halim
• Case Studies in Drug Discovery
• 35 min
  17. Current concepts for the management of patients with osteoporosis

  • Dr. Michael Lewiecki
• 35 min
  18. Discovery of Levetiracetam (Keppra(R)): The first SV2A ligand for the treatment of epilepsy

  • Dr. Henrik Klitgaard
• 36 min
  19. Teixobactin kills pathogens without detectable resistance

  • Prof. Kim Lewis
• 20 min
  20. Discovery of schizophrenia drug targets from DISC1 mechanisms

  • Prof. Atsushi Kamiya
• Archived Lectures *These may not cover the latest advances in the field
• 46 min
  21. CNS-drug design

  • Prof. Quentin Smith
• 38 min
  22. Imatinib as a paradigm of targeted cancer therapies

  • Prof. Brian Druker
• 44 min
  23. New and emerging treatments for osteoporosis

  • Dr. Michael Lewiecki
• 38 min
  24. Prodrugs and drug delivery

  • Prof. Jarkko Rautio

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Disclosure
3. Outline
4. Approved medications for osteoporosis
5. Limitations of current therapy
6. Bone structure - normal vs. osteoporosis
7. Bone remodeling
8. New and emerging treatments
9. Dmab inhibits osteoclast formation
10. Denosumab indications (USA)
11. FREEDOM extension (1)
12. FREEDOM extension (2)
13. FREEDOM extension summary
14. Why BMD continue to increase with Dmab?
15. Tissue selective estrogen complexes (TSEC)
16. CE/BZA approved by FDA
17. Estrogen, progesterone, SERMs
18. Combination – sequential therapy
19. Transdermal teriparatide
20. Transdermal microneedle delivery system
21. Oral PTH(1-34)
22. 5-CNAC carrier molecule
23. Oral recombinant calcitonin
24. PTH(1-34) microchip
25. Microchip mechanism of action
26. Teriparatide reduced risk of vertebral fractures
27. Abaloparatide (BA058)
28. Abaloparatide phase 2 and 3 studies
29. Abaloparatide phase 3 trial (active)
30. Risk of VFs fractures: Abalo vs. PBO
31. Risk of non-VFs: Abalo vs. PBO
32. Abaloparatide-TD
33. Wnt signaling pathway
34. Romosozumab (AMG 785)
35. Romosozumab phase 2 trial
36. Cathepsin K
37. Cathepsin K inhibitors
38. Odanacatib phase 2 trial: 3-year BMD data
39. Odanacatib phase 2 trial: bone turnover marker
40. Odanacatib phase 3: LOFT - BMD, fractures
41. Odanacatib phase 3: LOFT - safety
42. Challenges in drug development
43. ASBMR/NOF treat-to-target task force
44. Considerations
45. T-score goal
46. New strategies to improve care
47. The future for osteoporosis

Topics Covered

• Limitations of current therapy
• New data on available medications
• Recently approved treatments
• Novel targets for intervention
• Investigational agents
• New delivery systems
• Strategies to address unmet needs

Links

Series:

• Bone in Health and Disease
• Small Molecule Drug Discovery

Categories:

• Clinical Practice
• Pharmaceutical Sciences

Talk Citation

Publication History

• Published on March 31, 2016
• Archived on March 30, 2022

Financial Disclosures

• Dr. Michael Lewiecki acts as a consultant for Amgen, Merck, Lilly, Radius, Shire and Alexion. He also sits on the speaker's bureau for Shire and receives grants/research support as a Principal Investigator from Amgen, Merck and Lilly.